FDA Floats Oncology Authorization Shake-Up, Pitching ‘One-Trial’ Model for Accelerated and Full Approval

In draft guidance, the FDA outlined plans to move away from single-arm studies and instead favor randomized controlled trials that can potentially serve as the basis for both accelerated and full approval.
[Fierce Biotech]
Press Release

Stay up-to-date with your field!

Subscribe for free weekly science newsletters.

Related News